1.) We have demonstrated that the BRCA1 promoter and BRCA1 expression is controlled by a complex exchange of transcriptional co-repressors and co-activators including the BRCA1 protein itself. Reports that many cases of sporadic breast cancer show decreased expression of BRCA1 in the absence of BRCA1 mutation and loss of BRCA1 expression is associated with higher grade non-inherited breast cancer thus the goal of defining mechanisms of BRCA1 regulation at the level of transcription is highly significant. This is particularly important in view of recent description of promoter polymorphisms in the BRCA1 promoter that influence lifetime risk of breast cancer. 2.)BRCA1 transcriptional regulation in response to estrogen is driven by the displace or rearrangement of the transcription factor E2F-1 family at the BRCA1 promoter. Regulator exchange involves the cell type specific recruitment of Rb, p130, p107 and BRCA1 which in concert assist in recruiting the histone deacetylase 1 bound (HDAC1) CtBP1 co-repressor molecule in complex with CtIP. This assembly also includes the transcriptional co-activator p300. Following the addition of estrogen, E2F molecules are rearranged and p130, p107, CtBP and HDAC1 are displaced while p300 remains. This occurs with increase acetylation of the centrally positioned nucleosome and an increase in its accessibility to nuclease suggesting a more open chromatin structure at the BRCA1 promoter. 3.) Strikingly the influence of estrogen on the BRCA1 promoter in Breast cancer cells can be mimicked by the addition of the histone deacetylase inhibitor TSA. TSA causes a rapid estrogen-independent increase in BRCA1 transcription while by-passing any change in the assembly of co-activator and co-repressor complexes. The only net change in the promoter is the increase in histone acetylation and promoter accessibility as demonstrate by ChIP for acetylated histones and nuclease sensitivity. 4.) The role of CtBP in the response to metabolic status is well known and these finding suggest the BRCA1 expression may be uniquely responsive to metabolic status. The recent finding that elevated levels of BRCA1 expression controls the level of sirtuin expression suggest that BRCA1 may also be epistatic to factors and pathways that regulate the growth response to cellular energy homeostasis. 5.) The active control of chromatin marks, DNA accessibility and gene expression at the BRCA1 promoter by this metabolic switch provides an important molecular link between caloric intake and tumor suppressor expression in mammary cells. 6.) We now show that CtBP is upregulated in more aggressive forms of breast cancer and high expression predicts worse outcome in breast cancer. 7.) Moreover the list of genes targeted by CtBP classify tumors with worse clinical outcome. 8.) We have developed a drug screen assay to profile potential small molecule inhibitors of CtBP. 9.) We show that calorie restriction decrease the nuclear accumulation of CtBP and improved DNA repair in breast cancer cells.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Investigator-Initiated Intramural Research Projects (ZIA)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Byun, Jung S; Gardner, Kevin (2013) C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer. Int J Cell Biol 2013:647975
Byun, Jung S; Gardner, Kevin (2013) Wounds that will not heal: pervasive cellular reprogramming in cancer. Am J Pathol 182:1055-64
De Luca, P; Moiola, C P; Zalazar, F et al. (2013) BRCA1 and p53 regulate critical prostate cancer pathways. Prostate Cancer Prostatic Dis 16:233-8
De Siervi, Adriana; De Luca, Paola; Byun, Jung S et al. (2010) Transcriptional autoregulation by BRCA1. Cancer Res 70:532-42
De Siervi, Adriana; De Luca, Paola; Moiola, Cristian et al. (2009) Identification of new Rel/NFkappaB regulatory networks by focused genome location analysis. Cell Cycle 8:2093-100
Tongbai, Ron; Idelman, Gila; Nordgard, Silje H et al. (2008) Transcriptional networks inferred from molecular signatures of breast cancer. Am J Pathol 172:495-509
Yu, C; Zhang, X; Sun, G et al. (2008) RNA interference-mediated silencing of the polo-like kinase 1 gene enhances chemosensitivity to gemcitabine in pancreatic adenocarcinoma cells. J Cell Mol Med 12:2334-49
Wang, Rui-Hong; Zheng, Yin; Kim, Hyun-Seok et al. (2008) Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis. Mol Cell 32:11-20